These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 4661092)

  • 1. Serum-mediated blocking of cell-mediated anti-tumor immunity in a melanoma patient: association with BCG immunotherapy and clinical deterioration.
    Levy NL; Mahaley MS; Day ED
    Int J Cancer; 1972 Sep; 10(2):244-8. PubMed ID: 4661092
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro assay of cell-mediated immunity in BCG therapy of malignant melanoma: a preliminary report.
    Nathanson L; Clark DA
    Natl Cancer Inst Monogr; 1973 Dec; 39():221-4. PubMed ID: 4595321
    [No Abstract]   [Full Text] [Related]  

  • 3. Immunology and cutaneous malignant melanoma.
    Sober AJ
    Int J Dermatol; 1976; 15(1):1-18. PubMed ID: 1107238
    [No Abstract]   [Full Text] [Related]  

  • 4. Effect of chemotherapy and immunotherapy on tumor-specific immunity in melanoma.
    Mitchell MS; Mokyr MB; Davis JM
    J Clin Invest; 1977 Jun; 59(6):1017-26. PubMed ID: 863999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sequential studies on cell-mediated tumor immunity and blocking serum activity in ten patients with malignant melanoma.
    Hellström I; Warner GA; Hellström KE; Sjögren HO
    Int J Cancer; 1973 Mar; 11(2):280-92. PubMed ID: 4790696
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical and molecular insights into BCG immunotherapy for melanoma.
    Kremenovic M; Schenk M; Lee DJ
    J Intern Med; 2020 Dec; 288(6):625-640. PubMed ID: 32128919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results of administering B.C.G. to patients with melanoma.
    Grant RM; Mackie R; Cochran AJ; Murray EL; Hoyle D; Ross C
    Lancet; 1974 Nov; 2(7889):1096-100. PubMed ID: 4139404
    [No Abstract]   [Full Text] [Related]  

  • 8. Delayed cutaneous sensitivity reactions to extracts of autologous malignant melanoma: a second look.
    Bluming AZ; Vogel CL; Ziegler JL; Kiryabwire JW
    J Natl Cancer Inst; 1972 Jan; 48(1):17-24. PubMed ID: 4652371
    [No Abstract]   [Full Text] [Related]  

  • 9. A multiphase immunotherapy regimen for human melanoma: clinical and laboratory results.
    Levy NL; Seigler HF; Shingleton WW
    Cancer; 1974 Oct; 34(4 Suppl):suppl:1548-57. PubMed ID: 4421918
    [No Abstract]   [Full Text] [Related]  

  • 10. Mumps virus and BCG vaccine in metastatic melanoma.
    Minton JP
    Arch Surg; 1973 Apr; 106(4):503-6. PubMed ID: 4572347
    [No Abstract]   [Full Text] [Related]  

  • 11. [Immunologic reactions in malignant melanoma of the skin in man].
    Veresova OV; Korosteleva TA
    Vopr Onkol; 1975; 21(4):74-80. PubMed ID: 1105967
    [No Abstract]   [Full Text] [Related]  

  • 12. BCG in tumor immunotherapy.
    Baldwin RW; Pimm MV
    Adv Cancer Res; 1978; 28():91-147. PubMed ID: 360797
    [No Abstract]   [Full Text] [Related]  

  • 13. In vitro evidence of specific BCG-induced immunity to malignant melanoma in BALB-c mice.
    Faraci RP; Barone JJ; Marrone JC; Schour L
    J Natl Cancer Inst; 1974 Jun; 52(6):1913-5. PubMed ID: 4834418
    [No Abstract]   [Full Text] [Related]  

  • 14. [Development in the immunotherapy of malignant melanoma].
    Tritsch H
    Hautarzt; 1976 Jan; 27(1):1-7. PubMed ID: 767300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunology and immunotherapy of human-malignant melanoma: historic review and perspectives for the future.
    Gutterman JU; Mavligit G; Reed R; Richman S; McBride CE; Hersh EM
    Semin Oncol; 1975 Jun; 2(2):155-74. PubMed ID: 790574
    [No Abstract]   [Full Text] [Related]  

  • 16. BCG immunotherapy of malignant melanoma: summary of a seven-year experience.
    Morton DL; Eilber FR; Holmes EC; Hunt JS; Ketcham AS; Silverstein MJ; Sparks FC
    Ann Surg; 1974 Oct; 180(4):635-43. PubMed ID: 4412271
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunologic effects of BCG in patients with malignant melanoma: specific evidence for stimulation of the 'secondary' immune response.
    Chess L; Bock GN; Ungaro PC; Buchholz DH; Mardiney MR
    J Natl Cancer Inst; 1973 Jul; 51(1):57-65. PubMed ID: 4720886
    [No Abstract]   [Full Text] [Related]  

  • 18. BCG-induced protection against malignant melanoma: possible immunospecific effect in a murine system.
    Faraci RP; Barone J; Schour L
    Cancer; 1975 Feb; 35(2):372-7. PubMed ID: 1111914
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunology of human malignant melanoma.
    Lewis MG
    Ser Haematol; 1972; 5(5):44-65. PubMed ID: 4598040
    [No Abstract]   [Full Text] [Related]  

  • 20. Intralesional BCG, intravenous immune lymphocytes, and immunization with neuraminidase-treated tumor cells to manage melanoma; A clinical assessment.
    Seigler HF; Shingleton WW; Pickrell KL
    Plast Reconstr Surg; 1975 Mar; 55(3):294-8. PubMed ID: 1118487
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.